226 related articles for article (PubMed ID: 34026453)
1. Targeted Repolarization of Tumor-Associated Macrophages via Imidazoquinoline-Linked Nanobodies.
Bolli E; Scherger M; Arnouk SM; Pombo Antunes AR; Straßburger D; Urschbach M; Stickdorn J; De Vlaminck K; Movahedi K; Räder HJ; Hernot S; Besenius P; Van Ginderachter JA; Nuhn L
Adv Sci (Weinh); 2021 May; 8(10):2004574. PubMed ID: 34026453
[TBL] [Abstract][Full Text] [Related]
2. Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages.
Movahedi K; Schoonooghe S; Laoui D; Houbracken I; Waelput W; Breckpot K; Bouwens L; Lahoutte T; De Baetselier P; Raes G; Devoogdt N; Van Ginderachter JA
Cancer Res; 2012 Aug; 72(16):4165-77. PubMed ID: 22719068
[TBL] [Abstract][Full Text] [Related]
3. Large, Anionic Liposomes Enable Targeted Intraperitoneal Delivery of a TLR 7/8 Agonist To Repolarize Ovarian Tumors' Microenvironment.
Kang Y; Flores L; Ngai HW; Cornejo YR; Haber T; McDonald M; Moreira DF; Gonzaga JM; Abidi W; Zhang Y; Hammad M; Kortylewski M; Aboody KS; Berlin JM
Bioconjug Chem; 2021 Aug; 32(8):1581-1592. PubMed ID: 34289694
[TBL] [Abstract][Full Text] [Related]
4. Polymeric nanocapsules loaded with poly(I:C) and resiquimod to reprogram tumor-associated macrophages for the treatment of solid tumors.
Anfray C; Varela CF; Ummarino A; Maeda A; Sironi M; Gandoy S; Brea J; Loza MI; León S; Calvo A; Correa J; Fernandez-Megia E; Alonso MJ; Allavena P; Crecente-Campo J; Andón FT
Front Immunol; 2023; 14():1334800. PubMed ID: 38259462
[TBL] [Abstract][Full Text] [Related]
5. Single-domain antibody fusion proteins can target and shuttle functional proteins into macrophage mannose receptor expressing macrophages.
De Vlaeminck Y; Lecocq Q; Giron P; Heirman C; Geeraerts X; Bolli E; Movahedi K; Massa S; Schoonooghe S; Thielemans K; Goyvaerts C; Van Ginderachter JA; Breckpot K
J Control Release; 2019 Apr; 299():107-120. PubMed ID: 30797866
[TBL] [Abstract][Full Text] [Related]
6. Size-advantage of monovalent nanobodies against the macrophage mannose receptor for deep tumor penetration and tumor-associated macrophage targeting.
Erreni M; D'Autilia F; Avigni R; Bolli E; Arnouk SM; Movahedi K; Debie P; Anselmo A; Parente R; Vincke C; van Leeuwen FWB; Allavena P; Garlanda C; Mantovani A; Doni A; Hernot S; Van Ginderachter JA
Theranostics; 2023; 13(1):355-373. PubMed ID: 36593955
[No Abstract] [Full Text] [Related]
7. Targeted co-delivery of resiquimod and a SIRPα variant by liposomes to activate macrophage immune responses for tumor immunotherapy.
Jia D; Lu Y; Lv M; Wang F; Lu X; Zhu W; Wei J; Guo W; Liu R; Li G; Wang R; Li J; Yuan F
J Control Release; 2023 Aug; 360():858-871. PubMed ID: 37473808
[TBL] [Abstract][Full Text] [Related]
8. TLR 7/8 agonist reverses oxaliplatin resistance in colorectal cancer via directing the myeloid-derived suppressor cells to tumoricidal M1-macrophages.
Liu Z; Xie Y; Xiong Y; Liu S; Qiu C; Zhu Z; Mao H; Yu M; Wang X
Cancer Lett; 2020 Jan; 469():173-185. PubMed ID: 31629935
[TBL] [Abstract][Full Text] [Related]
9. Targeting MARCO and IL37R on Immunosuppressive Macrophages in Lung Cancer Blocks Regulatory T Cells and Supports Cytotoxic Lymphocyte Function.
La Fleur L; Botling J; He F; Pelicano C; Zhou C; He C; Palano G; Mezheyeuski A; Micke P; Ravetch JV; Karlsson MCI; Sarhan D
Cancer Res; 2021 Feb; 81(4):956-967. PubMed ID: 33293426
[TBL] [Abstract][Full Text] [Related]
10. Blocking LTB
Yan J; Zhu J; Li X; Yang R; Xiao W; Huang C; Zheng C
Phytomedicine; 2023 Oct; 119():154968. PubMed ID: 37531900
[TBL] [Abstract][Full Text] [Related]
11. PET Imaging of Macrophage Mannose Receptor-Expressing Macrophages in Tumor Stroma Using 18F-Radiolabeled Camelid Single-Domain Antibody Fragments.
Blykers A; Schoonooghe S; Xavier C; D'hoe K; Laoui D; D'Huyvetter M; Vaneycken I; Cleeren F; Bormans G; Heemskerk J; Raes G; De Baetselier P; Lahoutte T; Devoogdt N; Van Ginderachter JA; Caveliers V
J Nucl Med; 2015 Aug; 56(8):1265-71. PubMed ID: 26069306
[TBL] [Abstract][Full Text] [Related]
12. Peptide-guided resiquimod-loaded lignin nanoparticles convert tumor-associated macrophages from M2 to M1 phenotype for enhanced chemotherapy.
Figueiredo P; Lepland A; Scodeller P; Fontana F; Torrieri G; Tiboni M; Shahbazi MA; Casettari L; Kostiainen MA; Hirvonen J; Teesalu T; Santos HA
Acta Biomater; 2021 Oct; 133():231-243. PubMed ID: 33011297
[TBL] [Abstract][Full Text] [Related]
13. PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way.
Yu X; Long Y; Chen B; Tong Y; Shan M; Jia X; Hu C; Liu M; Zhou J; Tang F; Lu H; Chen R; Xu P; Huang W; Ren J; Wan Y; Sun J; Li J; Jin G; Gong L
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36253000
[TBL] [Abstract][Full Text] [Related]
14. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes.
Han S; Wang W; Wang S; Yang T; Zhang G; Wang D; Ju R; Lu Y; Wang H; Wang L
Theranostics; 2021; 11(6):2892-2916. PubMed ID: 33456579
[No Abstract] [Full Text] [Related]
15. Development of Toll-like Receptor Agonist-Loaded Nanoparticles as Precision Immunotherapy for Reprogramming Tumor-Associated Macrophages.
Zhang Y; Chen Y; Li J; Zhu X; Liu Y; Wang X; Wang H; Yao Y; Gao Y; Chen Z
ACS Appl Mater Interfaces; 2021 Jun; 13(21):24442-24452. PubMed ID: 34008947
[TBL] [Abstract][Full Text] [Related]
16. Polymersomes-Mediated Delivery of CSF1R Inhibitor to Tumor Associated Macrophages Promotes M2 to M1-Like Macrophage Repolarization.
Rodriguez-Perdigon M; Jimaja S; Haeni L; Bruns N; Rothen-Rutishauser B; Rüegg C
Macromol Biosci; 2022 Aug; 22(8):e2200168. PubMed ID: 35624036
[TBL] [Abstract][Full Text] [Related]
17. Targeting Pro-Tumoral Macrophages in Early Primary and Metastatic Breast Tumors with the CD206-Binding mUNO Peptide.
Lepland A; Asciutto EK; Malfanti A; Simón-Gracia L; Sidorenko V; Vicent MJ; Teesalu T; Scodeller P
Mol Pharm; 2020 Jul; 17(7):2518-2531. PubMed ID: 32421341
[TBL] [Abstract][Full Text] [Related]
18. Stimulating TAM-mediated anti-tumor immunity with mannose-decorated nanoparticles in ovarian cancer.
Glass EB; Hoover AA; Bullock KK; Madden MZ; Reinfeld BI; Harris W; Parker D; Hufnagel DH; Crispens MA; Khabele D; Rathmell WK; Rathmell JC; Wilson AJ; Giorgio TD; Yull FE
BMC Cancer; 2022 May; 22(1):497. PubMed ID: 35513776
[TBL] [Abstract][Full Text] [Related]
19. Marsdenia tenacissima extract disturbs the interaction between tumor-associated macrophages and non-small cell lung cancer cells by targeting HDGF.
Fu JL; Hao HF; Wang S; Jiao YN; Li PP; Han SY
J Ethnopharmacol; 2022 Nov; 298():115607. PubMed ID: 35973634
[TBL] [Abstract][Full Text] [Related]
20. Predicting the herbal medicine triggering innate anti-tumor immunity from a system pharmacology perspective.
Xiao Y; Zhang L; Zhu J; Zhang Y; Yang R; Yan J; Huang R; Zheng C; Xiao W; Huang C; Wang Y
Biomed Pharmacother; 2021 Nov; 143():112105. PubMed ID: 34560533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
